Page 3
-
Bristol Myers says next-gen blood cancer drug hits goal in key study
The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster Revlimid franchise.
-
Obesity drugs
Pfizer buys back into obesity drug chase with $4.9B Metsera deal
The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price amid enthusiasm for its weight loss medicines.
-
News roundup
FDA clears under-the-skin Keytruda; MBX shares double on study data
The clearance of Keytruda QLEX follows similar approvals for Bristol Myers and Roche. Elsewhere, MBX’s parathyroidism drug impressed investors and Roche claimed success in a breast cancer study.
-
IPO window
MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug
The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.
-
FDA clears first Barth syndrome drug amid scrutiny of rare disease stance
After an earlier rejection that drew criticism from some observers, the FDA quickly accepted Stealth BioTherapeutics’ new application and cleared its drug’s use.
-
Vaccines
CDC panel, recast by RFK Jr., softens COVID vaccine recommendations
After a tumultuous two-day meeting marked by confusion and missteps, an advisory committee endorsed guidelines that would urge people to discuss vaccination's benefits and risks with their physician.
-
Roche dives into MASH with $2.4B deal for 89bio
Roche’s CEO claimed 89bio’s drug, which is in late-stage testing, has the potential to show “best-in-disease efficacy” for many people with the condition.
-
Emerging biotech
A new biotech venture firm emerges, led by Bob Langer’s son
T.Rx Capital was co-founded by Michael Langer, former Pear Therapeutics CEO Corey McCann and Eli Lilly veteran Kwesi Frimpong-Boateng, and raised just shy of $80 million for its first fund.
-
News roundup
Arvinas reboots, cuts more staff; Porges joins Lazard
Pfizer and Arvinas plan to out-license their partnered drug vepdegestrant. Elsewhere, Novo shared more data for oral Wegovy and Vertex reached a deal in Italy for coverage of its gene editing medicine Casgevy.
-
Vaccines
CDC panel recommends splitting measles, varicella shots
The committee reconvened Friday to re-do a vote on coverage of the combined MMRV shot through the Vaccines for Children program, citing panelists’ confusion the day before.
Updated Sept. 19, 2025 -
Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs
The purchase gives Biogen full access to an implantable device that could help patients avoid the repeat lumbar punctures required for drugs like Spinraza.
-
Vaccines
CDC advisers postpone vote to delay some newborns’ hepatitis B shot
Members of ACIP voted to table a planned vote on withholding some infants’ first hepatitis B vaccine dose, adding more confusion to an already muddied meeting.
-
Vaccines
Fired CDC director says RFK Jr. aims to change childhood vaccine schedule
Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp changes.
-
Pharma reshoring
GSK ups US investment with $30B spending plan
The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there over pricing polices.
-
News roundup
Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD
Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”
-
Roivant pill succeeds in rare inflammatory disease trial
A drug licensed from Pfizer will be submitted to the FDA next year after study results showed it reduced dermatomyositis symptoms and steroid use.
-
Startup launches
Ollin debuts with $100M and plans to challenge top-selling eye drugs
Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.
-
CSL nabs option to acquire a startup and its blood-clotting drug
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding.
-
Startup launches
Former CinCor execs reunite to helm new biotech startup
Led by former founders of a biotech AstraZeneca acquired in 2023, AllRock Bio is starting out with a drug licensed from Sanofi that’ll be tested against pulmonary arterial hypertension.
-
Vaccines
A key CDC panel meets today to discuss vaccines. Here’s what to know.
The remade ACIP panel is set to vote today on recommendations for use of vaccines for measles and hepatitis B. They’ll meet again tomorrow to discuss COVID shots.
Updated Sept. 15, 2025 -
Novartis dives deeper into protein degraders with second Monte Rosa deal
The company’s new partnership with the "molecular glue” drug developer is broad, focused on immunology and could be worth up to $5.7 billion.
-
Foundation models are medtech’s newest trend. But what are they?
The AI models, which are built on massive datasets and can be adapted to multiple tasks, have become a part of medtech companies’ lexicon in the past few years.
-
ATyr shares plunge on trial miss in inflammatory lung disease
The company’s market value was largely wiped out after a therapy it’s been developing for pulmonary sarcoidosis missed its main study goal.
-
Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology
Early academic research suggests various ways weight loss drugs could have an impact in cancer care.
-
News roundup
Takeda poaches top Lilly exec; Maze soars on early PKU drug data
Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might have a “best-in-class” rare disease drug and Arrowhead challenged Ionis in court.
To find more content, use the "Topics" in the menu above.